Purpose: Data comparing traditional and novel anticoagulants are reviewed, and the potential use of new oral agents for the prevention and treatment of venous thromboembolism (VTE) is assessed.
Summary: Practical challenges in using traditional anticoagulants are well established and have led to the search for new oral agents. Apixaban, rivaroxaban, and dabigatran etexilate are new oral anticoagulants that may offer simpler, more effective, and safer treatment and prevention of VTE, which may increase adherence to such therapy, improve outcomes, and decrease overall health care costs. Their immediate onset of anticoagulant effect, ease of oral administration, and lack of needed regular anticoagulation monitoring are of interest in the medical and pharmacy communities. However, in the treatment and prevention of VTE, more data will be needed to determine their ultimate place in therapy. This review is intended to provide pharmacists with an objective overview of practical considerations that can help them understand the clinical data to facilitate their selection of anticoagulants.
Conclusion: Apixaban, rivaroxaban, and dabigatran etexilate are new oral agents for the prevention and treatment of VTE.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2146/ajhp110601 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design, Synthesis and Anti-Inflammatory Evaluation of 3-Substituted 5-Amidobenzoate Derivatives as Novel P2Y Receptor Antagonists via Structure-Guided Molecular Hybridization.
J Med Chem
January 2025
College of Chemistry, Zhengzhou University, Zhengzhou 450001, China.
The P2YR is activated by UDP and UDP glucose and is involved in many human inflammatory diseases. Based on the molecular docking analysis of currently reported P2YR antagonists and the crystallographic overlap study between PPTN and compound , a series of 3-substituted 5-amidobenzoate derivatives were designed, synthesized, and identified as promising P2YR antagonists. The optimal compound (methyl 3-(1-benzo[]imidazol-2-yl)-5-(2-(-tolyl) acetamido)benzoate, IC = 0.
View Article and Find Full Text PDFRefractory and Resistant Herpes Simplex Virus Mucocutaneous Infections in Immunocompromised Patients: Literature Review and Proposed Definitions for Use in Clinical Trials.
Clin Infect Dis
January 2025
Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Karolinska Comprehensive Cancer Center, Stockholm, Sweden.
Herpes simplex virus (HSV) infection is one of the most prevalent viral infections worldwide. In general, host immunity is sufficient to clear viral shedding and recurrences, although it is insufficient to prevent subsequent virologic reactivations. In immunocompromised patients, prolonged and difficult-to-treat HSV infections may develop.
View Article and Find Full Text PDFFlaxseed powder supplementation in non-alcoholic fatty liver disease: a randomized controlled clinical trial.
Food Funct
January 2025
Lianshui People's Hospital Affiliated to Kangda College of Nanjing Medical University, Huai'an, Jiangsu, 223400, China.
: Non-alcoholic fatty liver disease (NAFLD) has become a growing public health problem worldwide, and dietary interventions have important potential in the prevention and treatment of NAFLD. Moreover, previous animal studies have shown that flaxseed has a good improvement effect in animal NAFLD models. : Assess whether flaxseed powder could improve the liver lipid content in patients with NAFLD.
View Article and Find Full Text PDFPreparation and characterization of tildipirosin-loaded solid lipid nanoparticles for the treatment of intracellular infections.
Biomater Sci
January 2025
School of Chemistry, Chemical Engineering and Life Science, Hubei Key Laboratory of Nanomedicine for Neurodegenerative Diseases, Wuhan University of Technology, 122 Luoshi Road, Wuhan 430070, China.
To enhance the antibacterial efficacy of tildipirosin against (S.A.) infections, optimized solid lipid nanoparticles loaded with tildipirosin (SLN-TD) were developed, using docosanoic acid (DA), octadecanoic acid (OA), hexadecanoic acid (HA), and tetradecanoic acid (TA) as lipid components.
View Article and Find Full Text PDFPreventing and Treating Delayed Gastric Emptying (DGE) after Pancreatic Surgery: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Ann Surg
January 2025
Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Objective: To identify strategies to prevent and treat delayed gastric emptying (DGE) after pancreatic surgery.
Background: Among all complications of pancreatic surgery, DGE has the largest impact on prolonged hospital stay. Several randomized controlled trials (RCTs) have addressed DGE after pancreatic surgery, either as primary or as secondary outcome.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!